GBP3, while not broadly prognostic, exhibits glioblastoma-specific overexpression, activating p62-ERK1/2 and potentially aiding targeted diagnostics through RNA in situ hybridization, microarray analysis, or proteomic assays. This evidence concerns the gene MAPK3 and glioblastoma.